Recently Registered Midazolam Doses for Preterm Neonates Do Not Lead to Equal Exposure: A Population Pharmacokinetic Model

Swantje Voller*, Robert B. Flint, Fouzi Beggah, Irwin Reiss, Peter Andriessen, Luc J. Zimmermann, John N. van den Anker, Kian D. Liem, Birgit C. P. Koch, Saskia de Wildt, Catherijne A. J. Knibbe, Sinno H. P. Simons

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1300-1308
Number of pages9
JournalJournal of Clinical Pharmacology
Volume59
Issue number10
DOIs
Publication statusPublished - Oct 2019

Keywords

  • drug metabolism
  • fetal medicine
  • neonatology
  • pharmacokinetics
  • pharmacometrics
  • population pharmacokinetics
  • ORAL MIDAZOLAM
  • METABOLISM
  • SEDATION
  • INFANTS
  • LIVER

Cite this

Voller, S., Flint, R. B., Beggah, F., Reiss, I., Andriessen, P., Zimmermann, L. J., van den Anker, J. N., Liem, K. D., Koch, B. C. P., de Wildt, S., Knibbe, C. A. J., & Simons, S. H. P. (2019). Recently Registered Midazolam Doses for Preterm Neonates Do Not Lead to Equal Exposure: A Population Pharmacokinetic Model. Journal of Clinical Pharmacology, 59(10), 1300-1308. https://doi.org/10.1002/jcph.1429